Human Immunodeficiency Virus Type 1 Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major human immunodeficiency virus type 1 markets reached a value of US$ 24.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 39.8 Billion by 2034, exhibiting a growth rate (CAGR) of 4.56% during 2024-2034.
The human immunodeficiency virus type 1 market has been comprehensively analyzed in IMARC's new report titled "Human Immunodeficiency Virus Type 1 Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Human immunodeficiency virus type 1 (HIV-1) is a retrovirus that primarily targets cells of the immune system, particularly CD4+ T-helper cells, which play a crucial role in coordinating the immune response against infections. It is spread via direct contact of a mucosal membrane or the bloodstream with a bodily fluid containing HIV, such as semen, blood, vaginal secretions, and breast milk. The symptoms of this ailment can vary from person to person, and some patients may not experience any indications during the initial stages of infection. However, as the virus progresses and the immune system becomes severely compromised, the illness manifests as swollen lymph nodes, extreme fatigue, weakness, skin lesions, coughing, shortness of breath, rapid weight loss, persistent diarrhea, etc. The diagnosis of this ailment is typically based on the patient’s clinical features, medical history, and laboratory investigations. A healthcare provider may also perform several workups, including nucleic acid tests, enzyme-linked immunosorbent assay (ELISA), western blot, etc., to confirm the presence of HIV antibodies or viral antigens in the blood sample.
The increasing cases of intravenous drug use, which involves sharing needles and syringes, thereby enhancing the risk of viral transmission, are primarily driving the human immunodeficiency virus type 1 market. In addition to this, the rising incidence of unprotected sexual intercourse, that allows the pathogen to enter the bloodstream through tiny cuts, tears, or abrasions in the mucous membranes of the vagina, rectum, penis, or mouth, is also creating a positive outlook for the market. Moreover, the widespread adoption of integrase strand transfer inhibitors, including raltegravir, dolutegravir, elvitegravir, etc., since they help to prevent the integration of viral DNA into the host’s genetic material, is further bolstering the market growth. In line with this, the inflating application of pharmacokinetic enhancers, like ritonavir and cobicistat, in combination with various other antiretroviral drugs to improve treatment outcomes is acting as another significant growth-inducing factor. Additionally, the emerging popularity of therapeutic HIV vaccines, which aim to stimulate an immune response against the pathogen, thereby controlling the infection and slowing down the disease progression, is expected to drive the human immunodeficiency virus type 1 market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the human immunodeficiency virus type 1 market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for human immunodeficiency virus type 1 and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the human immunodeficiency virus type 1 market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the human immunodeficiency virus type 1 market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the human immunodeficiency virus type 1 market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current human immunodeficiency virus type 1 marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the human immunodeficiency virus type 1 market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the human immunodeficiency virus type 1 market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the human immunodeficiency virus type 1 market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of human immunodeficiency virus type 1 across the seven major markets?
What is the number of prevalent cases (2018-2034) of human immunodeficiency virus type 1 by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of human immunodeficiency virus type 1 by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with human immunodeficiency virus type 1 across the seven major markets?
What is the size of the human immunodeficiency virus type 1 patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of human immunodeficiency virus type 1?
What will be the growth rate of patients across the seven major markets?
Human Immunodeficiency Virus Type 1: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for human immunodeficiency virus type 1 drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the human immunodeficiency virus type 1 market?
What are the key regulatory events related to the human immunodeficiency virus type 1 market?
What is the structure of clinical trial landscape by status related to the human immunodeficiency virus type 1 market?
What is the structure of clinical trial landscape by phase related to the human immunodeficiency virus type 1 market?
What is the structure of clinical trial landscape by route of administration related to the human immunodeficiency virus type 1 market?
The human immunodeficiency virus type 1 market has been comprehensively analyzed in IMARC's new report titled "Human Immunodeficiency Virus Type 1 Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Human immunodeficiency virus type 1 (HIV-1) is a retrovirus that primarily targets cells of the immune system, particularly CD4+ T-helper cells, which play a crucial role in coordinating the immune response against infections. It is spread via direct contact of a mucosal membrane or the bloodstream with a bodily fluid containing HIV, such as semen, blood, vaginal secretions, and breast milk. The symptoms of this ailment can vary from person to person, and some patients may not experience any indications during the initial stages of infection. However, as the virus progresses and the immune system becomes severely compromised, the illness manifests as swollen lymph nodes, extreme fatigue, weakness, skin lesions, coughing, shortness of breath, rapid weight loss, persistent diarrhea, etc. The diagnosis of this ailment is typically based on the patient’s clinical features, medical history, and laboratory investigations. A healthcare provider may also perform several workups, including nucleic acid tests, enzyme-linked immunosorbent assay (ELISA), western blot, etc., to confirm the presence of HIV antibodies or viral antigens in the blood sample.
The increasing cases of intravenous drug use, which involves sharing needles and syringes, thereby enhancing the risk of viral transmission, are primarily driving the human immunodeficiency virus type 1 market. In addition to this, the rising incidence of unprotected sexual intercourse, that allows the pathogen to enter the bloodstream through tiny cuts, tears, or abrasions in the mucous membranes of the vagina, rectum, penis, or mouth, is also creating a positive outlook for the market. Moreover, the widespread adoption of integrase strand transfer inhibitors, including raltegravir, dolutegravir, elvitegravir, etc., since they help to prevent the integration of viral DNA into the host’s genetic material, is further bolstering the market growth. In line with this, the inflating application of pharmacokinetic enhancers, like ritonavir and cobicistat, in combination with various other antiretroviral drugs to improve treatment outcomes is acting as another significant growth-inducing factor. Additionally, the emerging popularity of therapeutic HIV vaccines, which aim to stimulate an immune response against the pathogen, thereby controlling the infection and slowing down the disease progression, is expected to drive the human immunodeficiency virus type 1 market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the human immunodeficiency virus type 1 market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for human immunodeficiency virus type 1 and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the human immunodeficiency virus type 1 market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the human immunodeficiency virus type 1 market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the human immunodeficiency virus type 1 market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current human immunodeficiency virus type 1 marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the human immunodeficiency virus type 1 market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the human immunodeficiency virus type 1 market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the human immunodeficiency virus type 1 market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of human immunodeficiency virus type 1 across the seven major markets?
What is the number of prevalent cases (2018-2034) of human immunodeficiency virus type 1 by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of human immunodeficiency virus type 1 by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with human immunodeficiency virus type 1 across the seven major markets?
What is the size of the human immunodeficiency virus type 1 patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of human immunodeficiency virus type 1?
What will be the growth rate of patients across the seven major markets?
Human Immunodeficiency Virus Type 1: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for human immunodeficiency virus type 1 drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the human immunodeficiency virus type 1 market?
What are the key regulatory events related to the human immunodeficiency virus type 1 market?
What is the structure of clinical trial landscape by status related to the human immunodeficiency virus type 1 market?
What is the structure of clinical trial landscape by phase related to the human immunodeficiency virus type 1 market?
What is the structure of clinical trial landscape by route of administration related to the human immunodeficiency virus type 1 market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - UNMET NEEDS
10 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - KEY ENDPOINTS OF TREATMENT
11 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - MARKETED PRODUCTS
11.1 List of Human Immunodeficiency Virus Type 1 Marketed Drugs Across the Top 7 Markets
11.1.1 Ziagen (Abacavir Sulfate) - GlaxoSmithKline
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Videx (Didanosine) - Bristol-Myers Squibb
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Emtriva (Emtricitabine) - Gilead Sciences
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Epivir (Lamivudine) - ViiV Healthcare
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Viread (Tenofovir Disoproxil Fumarate) - Gilead Sciences
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - PIPELINE DRUGS
12.1 List of Human Immunodeficiency Virus Type 1 Pipeline Drugs Across the Top 7 Markets
12.1.1 Cabotegravir - ViiV Healthcare
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Vesatolimod - Gilead Sciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Zinlirvimab+Teropavimab+Zinlirvimab - Gilead Sciences
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Lenacapavir - Gilead Sciences
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 B/F/TAF - Gilead Sciences
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Human Immunodeficiency Virus Type 1 - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Human Immunodeficiency Virus Type 1 - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Human Immunodeficiency Virus Type 1 - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Human Immunodeficiency Virus Type 1 - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Human Immunodeficiency Virus Type 1 - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Human Immunodeficiency Virus Type 1 - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Human Immunodeficiency Virus Type 1 - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Human Immunodeficiency Virus Type 1 - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Human Immunodeficiency Virus Type 1 - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Human Immunodeficiency Virus Type 1 - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Human Immunodeficiency Virus Type 1 - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Human Immunodeficiency Virus Type 1 - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Human Immunodeficiency Virus Type 1 - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Human Immunodeficiency Virus Type 1 - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Human Immunodeficiency Virus Type 1 - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Human Immunodeficiency Virus Type 1 - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Human Immunodeficiency Virus Type 1 - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Human Immunodeficiency Virus Type 1 - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Human Immunodeficiency Virus Type 1 - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Human Immunodeficiency Virus Type 1 - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Human Immunodeficiency Virus Type 1 - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Human Immunodeficiency Virus Type 1 - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Human Immunodeficiency Virus Type 1 - Access and Reimbursement Overview
16 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - UNMET NEEDS
10 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - KEY ENDPOINTS OF TREATMENT
11 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - MARKETED PRODUCTS
11.1 List of Human Immunodeficiency Virus Type 1 Marketed Drugs Across the Top 7 Markets
11.1.1 Ziagen (Abacavir Sulfate) - GlaxoSmithKline
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Videx (Didanosine) - Bristol-Myers Squibb
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Emtriva (Emtricitabine) - Gilead Sciences
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Epivir (Lamivudine) - ViiV Healthcare
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Viread (Tenofovir Disoproxil Fumarate) - Gilead Sciences
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - PIPELINE DRUGS
12.1 List of Human Immunodeficiency Virus Type 1 Pipeline Drugs Across the Top 7 Markets
12.1.1 Cabotegravir - ViiV Healthcare
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Vesatolimod - Gilead Sciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Zinlirvimab+Teropavimab+Zinlirvimab - Gilead Sciences
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Lenacapavir - Gilead Sciences
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 B/F/TAF - Gilead Sciences
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Human Immunodeficiency Virus Type 1 - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Human Immunodeficiency Virus Type 1 - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Human Immunodeficiency Virus Type 1 - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Human Immunodeficiency Virus Type 1 - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Human Immunodeficiency Virus Type 1 - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Human Immunodeficiency Virus Type 1 - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Human Immunodeficiency Virus Type 1 - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Human Immunodeficiency Virus Type 1 - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Human Immunodeficiency Virus Type 1 - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Human Immunodeficiency Virus Type 1 - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Human Immunodeficiency Virus Type 1 - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Human Immunodeficiency Virus Type 1 - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Human Immunodeficiency Virus Type 1 - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Human Immunodeficiency Virus Type 1 - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Human Immunodeficiency Virus Type 1 - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Human Immunodeficiency Virus Type 1 - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Human Immunodeficiency Virus Type 1 - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Human Immunodeficiency Virus Type 1 - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Human Immunodeficiency Virus Type 1 - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Human Immunodeficiency Virus Type 1 - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Human Immunodeficiency Virus Type 1 - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Human Immunodeficiency Virus Type 1 - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Human Immunodeficiency Virus Type 1 - Access and Reimbursement Overview
16 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
